These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 30477208)

  • 21. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
    Cai A; Kong X
    Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.
    Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN
    Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
    Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-swap editing for the correction of common Duchenne muscular dystrophy mutations.
    Chai AC; Chemello F; Li H; Nishiyama T; Chen K; Zhang Y; Sánchez-Ortiz E; Alomar A; Xu L; Liu N; Bassel-Duby R; Olson EN
    Mol Ther Nucleic Acids; 2023 Jun; 32():522-535. PubMed ID: 37215149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice.
    Karri DR; Zhang Y; Chemello F; Min YL; Huang J; Kim J; Mammen PPA; Xu L; Liu N; Bassel-Duby R; Olson EN
    Mol Ther Nucleic Acids; 2022 Jun; 28():154-167. PubMed ID: 35402069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery challenges for CRISPR-Cas9 genome editing for Duchenne muscular dystrophy.
    Padmaswari MH; Agrawal S; Jia MS; Ivy A; Maxenberger DA; Burcham LA; Nelson CE
    Biophys Rev (Melville); 2023 Mar; 4(1):011307. PubMed ID: 36864908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein.
    Egorova TV; Polikarpova AV; Vassilieva SG; Dzhenkova MA; Savchenko IM; Velyaev OA; Shmidt AA; Soldatov VO; Pokrovskii MV; Deykin AV; Bardina MV
    Mol Ther Methods Clin Dev; 2023 Sep; 30():161-180. PubMed ID: 37457303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
    Chemello F; Olson EN; Bassel-Duby R
    Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy.
    Zhu P; Wu F; Mosenson J; Zhang H; He TC; Wu WS
    Mol Ther Nucleic Acids; 2017 Jun; 7():31-41. PubMed ID: 28624206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duchenne muscular dystrophy: an updated review of common available therapies.
    Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
    Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
    Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
    Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.
    Long C; McAnally JR; Shelton JM; Mireault AA; Bassel-Duby R; Olson EN
    Science; 2014 Sep; 345(6201):1184-1188. PubMed ID: 25123483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method.
    Iyombe-Engembe JP; Ouellet DL; Barbeau X; Rousseau J; Chapdelaine P; Lagüe P; Tremblay JP
    Mol Ther Nucleic Acids; 2016 Jan; 5(1):e283. PubMed ID: 26812655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome Editing Gene Therapy for Duchenne Muscular Dystrophy.
    Hotta A
    J Neuromuscul Dis; 2015 Sep; 2(4):343-355. PubMed ID: 27858753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies.
    Chey YCJ; Arudkumar J; Aartsma-Rus A; Adikusuma F; Thomas PQ
    WIREs Mech Dis; 2023 Jan; 15(1):e1580. PubMed ID: 35909075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using CRISPR/Cas9 System to Knock out Exon 48 in
    Dara M; Razban V; Talebzadeh M; Moradi S; Dianatpour M
    Avicenna J Med Biotechnol; 2021; 13(2):54-57. PubMed ID: 34012519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping.
    Wang P; Li H; Zhu M; Han RY; Guo S; Han R
    Mol Ther Methods Clin Dev; 2023 Mar; 28():40-50. PubMed ID: 36588820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy.
    Lim KRQ; Nguyen Q; Dzierlega K; Huang Y; Yokota T
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32213923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.